A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

NCT02367794 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1021

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
DRUG: Carboplatin
DRUG: Nab-Paclitaxel
DRUG: Paclitaxel

Sponsor

Hoffmann-La Roche